Updated

Definium Therapeutics' LSD-based pill cleared a second clinical trial targeting anxiety, drawing renewed attention to the psychedelics sector, according to new reporting. The result adds to a growing body of clinical data supporting psychedelic compounds as potential treatments for mental-health conditions. The trial outcome is being closely watched by investors and drugmakers active in the psychedelics space, as successful clinical results could accelerate regulatory pathways and commercial interest in the sector.